Alector Inc (STU:0Z2)
€ 1.69 -0.07 (-3.98%) Market Cap: 167.26 Mil Enterprise Value: -238.19 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 55/100

Alector Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 12, 2022 / 09:25PM GMT
Release Date Price: €9.77 (-9.37%)
Matthew Kelsey Harrison;
Morgan Stanley, Research Division - Executive Director

Okay. Great. Well, good afternoon, everybody. Thanks for sticking around for our last session today. Really pleased to have Alector with us for the session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

So really pleased to have Arnon Rosenthal, who's the CEO; and Marc Grasso, the CFO with us. Arnon, I guess maybe a good place to start is just -- I mean, I know you probably do this a lot of the time, but I think it's always nice to just refocus on -- the focus here is immuno-neurology, which is, I think, different from some of the other neurodegeneration companies. So maybe just bring people back to sort of the underlying thesis for the company and how you think about the targets that you're focused on?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot